The implications of model–informed drug discovery and development for tuberculosis

Morris Muliaditan, Geraint R. Davies, Ulrika S. H. Simonsson, Stephen H. Gillespie, Oscar Della Pasqua

Research output: Contribution to journalArticlepeer-review

13 Citations (Scopus)
1 Downloads (Pure)

Abstract

Despite promising advances in the field and highly effective first-line treatment, an estimated 9.6 million people are still infected with tuberculosis (TB). Innovative methods are required to effectively transition the growing number of compounds into novel combination regimens. However, progression of compounds into patients occurs despite the lack of clear understanding of the pharmacokinetic-pharmacodynamic (PK/PD) relations. The PreDiCT-TB consortium was established in response to the existing gaps in TB drug development. The aim of the consortium is to develop new preclinical tools in concert with an in silico model-based approach, grounded in PKPD principles. Here, we highlight the potential impact of such an integrated framework on various stages in TB drug development and on the dose rationale for drug combinations.
Original languageEnglish
Pages (from-to)481-486
Number of pages6
JournalDrug Discovery Today
Volume22
Issue number3
Early online date28 Sept 2016
DOIs
Publication statusPublished - Mar 2017

Keywords

  • PKPD
  • Tuberculosis
  • Drug development
  • Modelling and simulation

Fingerprint

Dive into the research topics of 'The implications of model–informed drug discovery and development for tuberculosis'. Together they form a unique fingerprint.

Cite this